This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, L. Articles by Thibodeau, S. N. Search for Related Content PubMed PubMed Citation Articles by Wang, L. Articles by Thibodeau, S. N.

Role of HPC2/ELAC2 in Hereditary Prostate Cancer¹

Departments of Laboratory Medicine and Pathology [L. W., D. A. E., E. C., A. F. M., J. M. C., S. N. T.], Health Sciences Research [S. K. M., S. L. S., B. J. P., S. J. J., J. R. C., D. J. S.], and Urology [D. A. E., M. L. B.], Mayo Clinic and Foundation, Rochester, Minnesota 55905

The HPC2/ELAC2 gene on chromosome 17p was recently identified as a candidate gene for hereditary prostate cancer (HPC). To confirm these findings, we screened 300 prostate cancer patients (2 affected members/family) from 150 families with HPC for potential germ-line mutations using conformation-sensitive gel electrophoresis, followed by direct sequence analysis. The minimum criteria for our families with HPC was the presence of 3 affected men with prostate cancer. A total of 23 variants were identified, including 13 intronic and 10 exonic changes. Of the 10 exonic changes, 1 truncating mutation was identified, a Glu216Stop nonsense mutation. This nonsense variant was found in 2 of 3 affected men in a single family. The remaining nine alterations included five missense, three silent, and one variant in the 3' untranslated region. To additionally test for potential associations of polymorphic variants and increased risk for disease, we genotyped two common polymorphisms, Ser217Leu and Ala541Thr, in 446 prostate cancer patients from 164 families with HPC and 502 population-based controls. The frequency of the Leu217 variant was similar for patients (32.3%) and controls (31.8%), as was the frequency of the Thr541 variant (5.4% among patients versus 5.2% among controls). In contrast to previous reports, we found no association of the joint effects of Leu271 and Thr541 (odds ratio, 1.04; 95% confidence interval, 0.57–1.89). Overall, our results did not reveal any association between these two common polymorphisms and the risk for HPC. The finding of a nonsense mutation in the HPC2/ELAC2 gene confirms its potential role in genetic susceptibility to prostate cancer. However, our data also suggest that germ-line mutations of the HPC2/ELAC2 are rare in HPC and that the variants Leu217 and Thr541 do not appear to influence the risk for HPC. Cumulatively, these results suggest that alterations within the HPC2/ELAC2 gene play a limited role in genetic susceptibility to HPC.

This article has been cited by other articles:

				Y.-C. Chen, E. Giovannucci, P. Kraft, and D. J.Hunter Sequence variants of elaC homolog 2 (Escherichia coli) (ELAC2) gene and susceptibility to prostate cancer in the Health Professionals Follow-Up Study Carcinogenesis, May 1, 2008; 29(5): 999 - 1004. [Abstract] [Full Text] [PDF]

				H. Rennert, C. M. Zeigler-Johnson, K. Addya, M. J. Finley, A. H. Walker, E. Spangler, D. G.B. Leonard, A. Wein, S. B. Malkowicz, and T. R. Rebbeck Association of Susceptibility Alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with Prostate Cancer Severity in European American and African American Men Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 949 - 957. [Abstract] [Full Text] [PDF]

				G. Narla, A. DiFeo, H. L. Reeves, D. J. Schaid, J. Hirshfeld, E. Hod, A. Katz, W. B. Isaacs, S. Hebbring, A. Komiya, et al. A Germline DNA Polymorphism Enhances Alternative Splicing of the KLF6 Tumor Suppressor Gene and Is Associated with Increased Prostate Cancer Risk Cancer Res., February 15, 2005; 65(4): 1213 - 1222. [Abstract] [Full Text] [PDF]

				C. Cybulski, T. Huzarski, B. Gorski, B. Masojc, M. Mierzejewski, T. Debniak, B. Gliniewicz, J. Matyjasik, E. Zlowocka, G. Kurzawski, et al. A Novel Founder CHEK2 Mutation is Associated with Increased Prostate Cancer Risk Cancer Res., April 15, 2004; 64(8): 2677 - 2679. [Abstract] [Full Text] [PDF]

				D. J. Schaid The complex genetic epidemiology of prostate cancer Hum. Mol. Genet., April 1, 2004; 13(90001): R103 - 121. [Abstract] [Full Text] [PDF]

				C. Cybulski, B. Gorski, T. Debniak, B. Gliniewicz, M. Mierzejewski, B. Masojc, A. Jakubowska, J. Matyjasik, E. Zlowocka, A. Sikorski, et al. NBS1 Is a Prostate Cancer Susceptibility Gene Cancer Res., February 15, 2004; 64(4): 1215 - 1219. [Abstract] [Full Text] [PDF]

				E. H. Seppala, T. Ikonen, V. Autio, A. Rokman, N. Mononen, M. P. Matikainen, T. L. J. Tammela, and J. Schleutker Germ-Line Alterations in MSR1 Gene and Prostate Cancer Risk Clin. Cancer Res., November 1, 2003; 9(14): 5252 - 5256. [Abstract] [Full Text] [PDF]

				J. L. Stanford, L. P. Sabacan, E. A. Noonan, L. Iwasaki, J. Shu, Z. Feng, and E. A. Ostrander Association of HPC2/ELAC2 Polymorphisms with Risk of Prostate Cancer in a Population-based Study Cancer Epidemiol. Biomarkers Prev., September 1, 2003; 12(9): 876 - 881. [Abstract] [Full Text] [PDF]

				R. K. Nam, W. W. Zhang, J. Trachtenberg, E. Diamandis, A. Toi, M. Emami, M. Ho, J. Sweet, A. Evans, M. A.S. Jewett, et al. Single Nucleotide Polymorphism of the Human Kallikrein-2 Gene Highly Correlates With Serum Human Kallikrein-2 Levels and in Combination Enhances Prostate Cancer Detection J. Clin. Oncol., June 15, 2003; 21(12): 2312 - 2319. [Abstract] [Full Text] [PDF]

				G. Severi, G. G. Giles, M. C. Southey, A. Tesoriero, W. Tilley, P. Neufing, H. Morris, D. R. English, M. R. E. McCredie, P. Boyle, et al. ELAC2/HPC2 Polymorphisms, Prostate-Specific Antigen Levels, and Prostate Cancer J Natl Cancer Inst, June 4, 2003; 95(11): 818 - 824. [Abstract] [Full Text] [PDF]

				H. Takaku, A. Minagawa, M. Takagi, and M. Nashimoto A candidate prostate cancer susceptibility gene encodes tRNA 3' processing endoribonuclease Nucleic Acids Res., May 1, 2003; 31(9): 2272 - 2278. [Abstract] [Full Text] [PDF]

				K. Hemminki and K. Czene Attributable Risks of Familial Cancer from the Family-Cancer Database Cancer Epidemiol. Biomarkers Prev., December 1, 2002; 11(12): 1638 - 1644. [Abstract] [Full Text] [PDF]

				T. R. Rebbeck Inherited Genotype and Prostate Cancer Outcomes Cancer Epidemiol. Biomarkers Prev., October 1, 2002; 11(10): 945 - 952. [Abstract] [Full Text] [PDF]

				J. Simard, M. Dumont, P. Soucy, and F. Labrie Perspective: Prostate Cancer Susceptibility Genes Endocrinology, June 1, 2002; 143(6): 2029 - 2040. [Full Text] [PDF]

				Y.-Q. Wu, H. Chen, M. A. Rubin, K. J. Wojno, and K. A. Cooney Loss of Heterozygosity of the Putative Prostate Cancer Susceptibility Gene HPC2/ELAC2 Is Uncommon in Sporadic and Familial Prostate Cancer Cancer Res., December 1, 2001; 61(24): 8651 - 8653. [Abstract] [Full Text] [PDF]